The Oncobiologics Team

Oncobiologics was formed by a team of accomplished scientists and engineers with over 100 years of experience in major pharmaceutical and biotech companies. The team brings senior management and technical experience from top-tier organizations, including; Amgen, Genentech, Eli Lilly, Bristol-Myers Squibb, Pfizer, Bayer, Merck, Johnson & Johnson, Schering-Plough and Medarex.

Oncobiologics combines the world-class know-how of leading discovery and development scientists with the agile, innovative culture of a start-up. We have also developed an expert advisory team and partnerships with leading institutions to complement our capabilities.

EXECUTIVE TEAM

Pankaj Mohan, Ph.D.

Founder and CEO

Dr. Mohan founded Oncobiologics in 2011 after a distinguished 20+ year career in the global biopharmaceutical industry.  Most recently, Dr. Mohan headed  Business Operations and Portfolio Management for a division of Bristol-Myers Squibb, where he was instrumental in expanding the business’ biologics pipeline.  He also held prior positions at Genentech and Eli Lilly and Company, where he led various bioprocess engineering functions.   Dr. Mohan also served as Assistant Professor (Lecturer/Fellow), at the Advanced Centre for Biochemical Engineering  at University College London.

During his career, Dr. Mohan played an important role in the development and manufacture of multiple blockbuster biopharmaceutical drugs. He planned, initiated and led a state of the art biologics R&D organization, and most recently led the acquisition of small biotech companies and multiple biologics molecule assets.

He earned his Ph.D. in Biochemical  Engineering at the School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom;  his MBA specializing in Finance Management from Middlesex University Business School, London, United Kingdom, and his Bachelor of Chemical Engineering at the Indian Institute of Technology in India.  Dr. Mohan also participated in the Executive Management program at the Fuqua School of Business, Duke University.

Dr. Mohan has authored a book on Pharmaceutical Manufacturing published by McGraw Hill and is the author of more than 30 publications.

 

John K. Cini. Ph.D.

Vice President – Discovery & Development Sciences

Dr. Cini is Vice President of Discovery & Developmental Sciences and is responsible for leading the company's discovery and development programs for novel cancer and immune disease therapies. Prior to joining Oncobiologics, Dr. Cini held senior scientific and technical leadership positions at Medarex (acquired by Bristol-Myers Squibb in 2010). Previous positions included scientific roles at Johnson & Johnson, Alexion, and Bayer. He is the holder of several product and formulation patents and has led several successful molecules through development and commercialization including immuno-oncology products.  Dr. Cini earned his Ph.D. in Biochemistry from the University of North Texas.

 

Scott Gangloff

Vice President — Process Development and Manufacturing

Scott joined Oncobiologics in 2011 with more than 15 years of experience in biopharmaceutical process development and cGMP manufacturing. He previously spent over 12 years at Bristol-Myers Squibb, where he led multiple biologics programs through process development, scale-up, clinical manufacturing, and transfer to commercial manufacturing. Scott also spent time with Jacobs Engineering as a Process Engineer. Scott brings an accomplished track record of leadership in developing and scaling-up processes designed for production of mAbs, fAbs, and PEGylated proteins through both mammalian and microbial expression systems. By integrating process development with clinical manufacturing, an emphasis on process design for manufacture enables rapid progression of molecules from DNA to FIH. Scott earned his Master’s in Chemical Engineering from Lehigh University and his Bachelors in Chemical Engineering from Villanova University.

 

Donald J. Griffith, C.P.A.

Chief Financial Officer

Don Griffith brings to Oncobiologics more than 30 years of experience in finance and accounting, including a partner position in the New Jersey accounting firm of Stolz & Griffith. Previously, his  roles included CFO and financial leadership positions  and more than 10 years in corporate finance with Exxon corporation. Don is a member of New Jersey Society of CPAs and the American Institute of CPAs.

 

Stephen J. McAndrew, Ph.D.

Vice President, Business Development

Dr. McAndrew is Vice President of Business Development and is responsible for the company’s revenue growth strategy and initiatives, establishing and managing all collaborative research and commercial product partnerships, and sourcing selected investment opportunities.

Prior to joining Oncobiologics, Dr. McAndrew served as Vice President, Business Development for Xenogen Biosciences, Caliper Life Sciences and Taconic Biosciences, where he was responsible for managing new business development, licensing and marketing functions. Previously, he served as Vice President, Pharmaceutical Business Development for Lexicon Pharmaceuticals and Director, Biotechnology Licensing for Bristol-Myers Squibb Company.  In each case, he was responsible for identifying, evaluating, negotiating and managing numerous preclinical compound collaborations and innovative platform technology alliances.  Prior to transitioning to Business Development/Licensing roles, Dr. McAndrew led applied research programs within Discovery-Oncology at Bristol-Myers Squibb, and exploratory research in the Roche Institute of Molecular Biology at Hoffmann La-Roche.

Dr. McAndrew earned his Ph.D. in Cellular and Molecular Biology from Ohio University, his Masters of Science in Molecular Genetics from SUNY at Albany and his Bachelors of Science from SUNY at Oswego.

 

Elizabeth Yamashita

Vice President, Regulatory Affairs

Liz is Vice President of Regulatory Affairs and is responsible for Oncobiologics’ regulatory strategies and operations as well as clinical programs.  She brings over 30 years of pharmaceutical industry experience with 20+ years in the Regulatory Affairs arena. Prior to joining Oncobiologics, Liz served as Group Vice President, Regulatory Affairs at Savient Pharmaceuticals, Inc. In this role, she managed all aspects of the regulatory function, and recently led the Savient team to its first European marketing approval for Krystexxa® (pegloticase), a PEGylated enzyme for the treatment of severe gout.  Prior to this position, she served as Principal Fellow at ImClone, providing regulatory expertise across the ImClone and Eli Lilly biotech pipelines.  As Vice President at ImClone Systems, she was responsible for Regulatory CMC strategy and Operations for development and commercial monoclonal antibody projects.  Liz began her career at Bristol-Myers Squibb holding positions in Regulatory CMC, Process Chemistry, and global Oncology marketing.

Liz earned her Regulatory Affairs Certification from RAPS in 2002, and holds a B.S. degree in Chemistry from the University of Rochester.

 

Richard C. Gregory

Director of Marketing & Communications

Rick Gregory brings more than 20 years of strategic marketing experience to Oncobiologics. As an independent consultant, he has led dozens of life sciences strategy and execution engagements with leading firms such as GE Healthcare Life Sciences, Oncogene Sciences (OSI, now part of Astellas), CARR-Centritech, Xcellerex, Natrix Separations, FTS Systems, Sepracor, VWR International and Mayo Medical Laboratories.  He is also the author of the bestselling business book, The Dollarization Discipline, published by John Wiley & Sons in 2004.  Rick earned his B.A. in Economics from Amherst College.


 

inVentiv Health Partnership:  Key Leaders
 

Patricia A. Mosher
Senior Vice President
Global Alliance Management

Ms. Patricia A. Mosher is responsible for the overall Oncobiologics/inVentiv relationship and ensuring successful service delivery across all inVentiv business units, as well as all therapeutic and functional areas for Oncobiologics. Ms. Mosher provides continuous executive sponsorship, oversight of the relationship and portfolio execution. Ms. Mosher has been in the industry for 29 years and has been with inVentiv Health Clinical for 17 years.   Prior to her role in Alliance Management, Ms. Mosher was the Therapeutic Head of General Medicine/VID Division and provided operational oversight to all programs conducted within her division. She has experience in the management of global trials from Phase I-IV in both pediatric and adult patient populations with stem cells, vaccines, devices and drug compounds in the treatment of such indications as h. pylori disease, Chron’s, UC, HIV, HCV, MDR-TB, complicated hospital infections, sepsis, hemorrhagic trauma, meningococcal disease, HPV, catheter site infections, CKD, influenzae, upper and lower respiratory tract infections, pulmonary mycosis, COPD, allergic rhinitis, diabetes, OA/RA, dermatophyte infections. Prior to joining inVentiv Health Clinical, Ms. Mosher was involved in studies that led to the approval of itraconazole in the treatment of histoplasmosis and blastomycosis in HIV/AIDS patients, as well as the dermatophyte infection trials with this compound.
 

Marty Birkhofer, MD
Chief Medical Advisor

Dr. Birkhofer brings a wealth of experience to the Oncobiologics/inVentiv partnership, with extensive leadership experience in all facets of clinical development, medical affairs and business development. A 20-year veteran of Bristol-Myers Squibb, Dr. Birkhofer most recently served as Vice President, Business Development, leading global search, evaluation, and diligence for the company’s worldwide business development interests. Previously, he managed global medical affairs for oncology. Notably, Dr. Birkhofer led the development, launch and life cycle management of Erbitux® in colorectal cancer as well as head and neck tumors. Dr. Birkhofer’s earlier roles included overseeing the BMS oncology clinical research team in Europe and providing clinical pharmacology support for all small molecule and biologic assets in oncology, immunology and anti-infective therapeutic areas. As Chief Medical Advisor, Dr. Birkhofer drives strategic investment in areas that further expand the partnership, leverages medical and scientific expertise in development strategy, and advises the business on trends and issues.